Opendata, web and dolomites

BILITOLERANCE SIGNED

Control of disease tolerance to infection by Biliverdin Reductase A

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BILITOLERANCE project word cloud

Explore the words cloud of the BILITOLERANCE project. It provides you a very rough idea of what is the project "BILITOLERANCE" about.

hypothesis    imposed    tissues    oxygenase    cells    deleterious    shaped    peroxidation    lipid    disease    tolerance    characterizing    unexplored    bvra    coupled    relies    effector    infection    mechanism    said    illustrated    activation    mechanisms    chain    sequestering    led    presumably    evolutionary    clearance    strategy    conversion    catabolizing    carry    defense    tissue    multiple    hydrocarbon    catabolism    containment    of    survival    iron    bilirubin    oxidative    selective    pathogens    oxidant    bilitolerance    protein    negative    countervailing    pro    modulate    direct    potent    provides    compromising    function    damage    conserved    receptor    health    expression    expulsion    ahr    heme    tested    enzyme    central    confer    preserve    primarily    anti    possibly    immunopathology    functional    host    limits    reductase    resistance    evolution    stress    limit    offs    output    ferritin    pathogen    lipophilic    aryl    trade    resident    macrophages    infections    pressure    emergence    signals    biliverdin    fitness    immune    exerting    genes    parenchyma   

Project "BILITOLERANCE" data sheet

The following table provides information about the project.

Coordinator
FUNDACAO CALOUSTE GULBENKIAN 

Organization address
address: AVENIDA BERNA 45
city: LISBOA
postcode: 1000
website: www.igc.gulbenkian.pt

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Portugal [PT]
 Total cost 160˙635 €
 EC max contribution 160˙635 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2016
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2018
 Duration (year-month-day) from 2018-12-01   to  2021-02-04

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACAO CALOUSTE GULBENKIAN PT (LISBOA) coordinator 160˙635.00

Map

 Project objective

The immune system was shaped through evolution, primarily through the selective pressure imposed by pathogens. This led to the emergence of multiple mechanisms that limit the negative impact of pathogens on host health and fitness. The best recognized defense strategy against infections relies on resistance mechanisms that aim at pathogen containment, expulsion or clearance. While crucial for host survival to infection, resistance mechanisms can carry significant trade-offs, often driven by oxidative stress and damage imposed to host parenchyma cells, and in some cases compromising the functional output of host tissues, i.e. immunopathology. Presumably for this reason, resistance mechanisms are coupled to countervailing oxidative stress responses that preserve parenchyma tissue function. These provide tissue damage control without exerting a direct negative impact on pathogens and as such are said to confer disease tolerance to infection. This defense strategy relies on the expression of a number of evolutionary conserved effector genes controlling the pro-oxidant effects of iron and heme, as illustrated for the heme catabolizing enzyme heme oxygenase 1 or the iron sequestering protein ferritin H chain. BILITOLERANCE aims at identifying and characterizing an unexplored and possibly central component of this tissue damage control mechanism that relies on the conversion of the end-product of heme catabolism biliverdin into bilirubin, by biliverdin reductase A (BVRA). The central hypothesis to be tested by BILITOLERANCE is that bilirubin generated by BVRA provides a potent lipophilic anti-oxidant defense mechanism that limits the deleterious effects of lipid peroxidation. Moreover BILITOLERANCE will test the hypothesis that bilirubin also signals via the aryl hydrocarbon receptor (AhR) to modulate the activation of tissue-resident macrophages and promote tissue damage control and disease tolerance to infection.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BILITOLERANCE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BILITOLERANCE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

5G-ACE (2019)

Beyond 5G: 3D Network Modelling for THz-based Ultra-Fast Small Cells

Read More  

MacMeninges (2019)

Control of Central Nervous Sytem inflammation by meningeal macrophages, and its impairment upon aging

Read More  

IMPRESS (2019)

Integrated Modular Power Conversion for Renewable Energy Systems with Storage

Read More